Evolution of the Average Target: Cochlear Limited

Evolution of the Average Target - Cochlear Limited

Evolution of the Target Price: Cochlear Limited

Evolution of the Target Price - Cochlear Limited

Changes in Analyst Recommendations: Cochlear Limited

bc42.Y7O7cRCCUjbra1v1nGbUxbinDOnZQmTZezd0gulRYcg.KcDtGXTMF0zSOSKX3ien9I_PRrG9CAuwHkMiwIEYCbEgwY01XNJ_YKASYw~5911272c711dca3d6c9584081f4c57d4
07-23 Jefferies Downgrades Cochlear to Hold from Buy; Price Target is AU$128.40 MT
04-30 Cochlear Needs to Keep Promoting Implants as Volume Delays Not Structural, Says Jefferies, Shares Up 4% MT
04-23 Jarden Adjusts Cochlear's Price Target to AU$169 from AU$224, Keeps at Neutral MT
04-22 Analyst recommendations: Meta, Amazon, Booking, Goldman Sachs, Moderna… Zonebourse
04-22 Cochlear's Guidance Cut 'Far Worse Than Anticipated,' Multiple Also at Risk, Jarden Says MT
03-17 Cochlear Poised for Medium-Term Growth on Nexa Launch, Jefferies Says MT
03-01 Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says MT
02-02 Cochlear Expected to Grow Market Share With Implant, Processor Products, Jefferies Says MT
25-08-18 Jarden Adjusts Cochlear's Price Target to AU$278.51 from AU$270.28, Keeps at Neutral MT
25-08-17 Cochlear's Fiscal 2025 Revenue Weighed Down by Uncertainty of Implant Launch; Innovation Key to Boosting Market Share, Jarden Says MT
25-06-18 UBS Upgrades Cochlear to Buy from Neutral, Price Target is AU$325 MT
25-02-16 Cochlear's Fiscal H1 Results Miss 'Disappointing,' Jarden Research Says MT
25-02-14 Jefferies Upgrades Cochlear to Buy from Hold; Price Target is AU$308 MT
24-10-31 Macquarie Upgrades Cochlear to Neutral from Underperform, Price Target is AU$289 MT
24-08-16 Jarden Research Adjusts Cochlear Limited's Price Target to AU$262.22 From AU$244.36, Keeps at Neutral MT
24-03-05 Morgan Stanley Adjusts Cochlear’s Price Target to AU$276 From AU$258, Keeps at Underweight MT
24-02-19 Jarden Research Adjusts Cochlear’s Price Target to AU$244.35 From AU$237.17, Keeps at Neutral MT
24-02-08 Jarden Research Adjusts Cochlear's Price Target to AU$237.17 From AU$229.20, Keeps at Neutral MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-12.3%
+7.82%
+2.77%
+4.48%
+11.41%
+11.8%
-7.7%
+6.08%
+36.89%
+20.39%
Average +8.16%
Weighted average by Cap. +8.14%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
155.47AUD
Average target price
136.34AUD
Spread / Average Target
-12.30%
High Price Target
165.00AUD
Spread / Highest target
+6.13%
Low Price Target
110.00AUD
Spread / Lowest Target
-29.25%

Analyst Consensus Detail

Analyst consensus - Cochlear Limited

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Cochlear Limited
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Cochlear Limited
  1. Stock Market
  2. Stocks
  3. COH Stock
  4. Consensus Cochlear Limited